Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341. (Q39587305)

13 September 2017

title

Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341. (English)

1 reference

13 September 2017

1 reference

12

Shixuan Wang

1 reference

13 September 2017

Yong Fang

1

1 reference

13 September 2017

Yi Hu

2

1 reference

13 September 2017

Peng Wu

3

1 reference

13 September 2017

Beibei Wang

4

1 reference

13 September 2017

Yuan Tian

5

1 reference

13 September 2017

Xi Xia

6

1 reference

13 September 2017

Qinghua Zhang

7

1 reference

13 September 2017

Tong Chen

8

1 reference

13 September 2017

Xuefeng Jiang

9

1 reference

13 September 2017

Quanfu Ma

10

1 reference

13 September 2017

Gang Xu

11

1 reference

13 September 2017

Jianfeng Zhou

13

1 reference

13 September 2017

Ding Ma

14

1 reference

13 September 2017

Li Meng

15

1 reference

13 September 2017

publication date

23 February 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

29

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

247-252

1 reference

The biology of ovarian cancer: new opportunities for translation

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Development of histone deacetylase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Histone deacetylase inhibitors: gathering pace

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

How the ubiquitin-proteasome system controls transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Histone deacetylase inhibitors as anti-neoplastic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

p21 in cancer: intricate networks and multiple activities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496756

10.3109/07357907.2010.496756

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference